<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0001712'>Left ventricular hypertrophy</z:hpo> (LVH), an independent risk factor for cardiovascular (CV) morbidity and mortality, recognizes a multifactorial pathogenesis </plain></SENT>
<SENT sid="1" pm="."><plain>A plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> value ≥155 mg/dL for the 1-h postload plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> during an oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test (OGTT) identifies subjects with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance (NGT) at high risk for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>We addressed the question if <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance status, particularly 1-h postload plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> levels, affects left ventricular mass (LVM) and cardiac geometry in essential <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: We enrolled 767 never-treated hypertensive subjects, 393 women and 374 men (mean age 49.6 ± 8.5 years) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent an OGTT for the evaluation of <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance and standard echocardiography </plain></SENT>
<SENT sid="5" pm="."><plain>LVM was calculated using the Devereux formula and normalized by body surface area (LVM index [LVMI]) </plain></SENT>
<SENT sid="6" pm="."><plain>Insulin sensitivity was assessed by the Matsuda index </plain></SENT>
<SENT sid="7" pm="."><plain>Among <z:hpo ids='HP_0000001'>all</z:hpo> participants, 514 had NGT, 168 had <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT), and 85 had type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>According to the 1-h postload plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> cutoff point of 155 mg/dL, we divided normotolerant subjects into two groups: NGT &lt;155 mg/dL (n = 356) and NGT ≥155 mg/dL (n = 158) </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: Subjects in the NGT ≥155 mg/dL group had worse insulin sensitivity than subjects in the NGT &lt;155 mg/dL group (Matsuda index 63.9 vs. 88.8; P &lt; 0.0001) </plain></SENT>
<SENT sid="10" pm="."><plain>Men with NGT ≥155 mg/dL had a higher LVMI than men with NGT &lt;155 mg/dL (126.6 vs. 114.3 g/m(2); P = 0.002) and a different LVH prevalence (41.1 vs. 25.8%; P &lt; 0.0001) </plain></SENT>
<SENT sid="11" pm="."><plain>At multiple regression analysis, 1-h <z:chebi fb="105" ids="17234">glucose</z:chebi> resulted in the major determinant of LVMI in normotolerant, IGT, and diabetic groups </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: These data show that NGT ≥155 mg/dL subjects, compared with NGT &lt;155 mg/dL subjects, have a higher LVMI and a greater prevalence of LVH similar to that of IGT and diabetic patients </plain></SENT>
</text></document>